Dashboard
1
Poor Management Efficiency with a low ROCE of 5.32%
- The company has been able to generate a Return on Capital Employed (avg) of 5.32% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -7.73% and Operating profit at -141.03% over the last 5 years
3
The company has declared positive results in Mar'2026 after 4 consecutive negative quarters
4
With ROE of 1.20%, it has a expensive valuation with a 1.35 Price to Book Value
5
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
73.86%
0%
73.86%
6 Months
65.1%
0%
65.1%
1 Year
98.49%
0%
98.49%
2 Years
52.22%
0%
52.22%
3 Years
20.55%
0%
20.55%
4 Years
40.37%
0%
40.37%
5 Years
34.61%
0%
34.61%
Qianjiang Yongan Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-7.73%
EBIT Growth (5y)
-141.03%
EBIT to Interest (avg)
11.99
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.41
Tax Ratio
22.15%
Dividend Payout Ratio
128.53%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.55%
ROE (avg)
4.31%
Valuation key factors
Factor
Value
P/E Ratio
125
Industry P/E
Price to Book Value
1.50
EV to EBIT
-1657.85
EV to EBITDA
24.34
EV to Capital Employed
1.89
EV to Sales
2.50
PEG Ratio
NA
Dividend Yield
1.97%
ROCE (Latest)
-0.11%
ROE (Latest)
1.20%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
327.80
235.90
38.96%
Operating Profit (PBDIT) excl Other Income
75.10
38.90
93.06%
Interest
0.00
0.00
Exceptional Items
0.10
-3.50
102.86%
Consolidate Net Profit
34.80
8.00
335.00%
Operating Profit Margin (Excl OI)
143.10%
45.50%
9.76%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 38.96% vs 14.51% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 335.00% vs 186.96% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
779.30
834.90
-6.66%
Operating Profit (PBDIT) excl Other Income
108.50
151.80
-28.52%
Interest
1.10
0.80
37.50%
Exceptional Items
-17.50
-22.80
23.25%
Consolidate Net Profit
7.20
59.70
-87.94%
Operating Profit Margin (Excl OI)
-10.70%
46.60%
-5.73%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -6.66% vs -13.86% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -87.94% vs 310.21% in Dec 2024
About Qianjiang Yongan Pharmaceutical Co., Ltd. 
Qianjiang Yongan Pharmaceutical Co., Ltd.
Specialty Chemicals
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






